spinal muskelatrofi – Å leva med polyartritt (cP)

Verna:

Medicinrådets maktdemonstrasjon er for hele landet og pasientene for dyrt

Lisbeth ex direktør fra Muskelsvindfonden har dette debatindlæg i dagens utgave.

Når en autoritet spiller poker på bekostning av pasienter.

Er det fortsatt etisk hva som skjer i Danmark?

European Marketing Authorization Application for Evrysdi™ (risdiplam)

PTC announced the acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA). The EMA previously granted PRIME (PRIority Medicines) designation to risdiplam for the treatment of people with SMA, providing a pathway for accelerated evaluation by the agency. The milestone triggers a $15 million payment to PTC from Roche.

The U.S. Food and Drug Administration recently approved Evrysdi™ (risdiplam) for the treatment of SMA for adults and children 2 months and older. Evrysdi™ (risdiplam) is based on PTC science and is commercialized in the United States by Genentech, a member of the Roche Group. Evrysdi™ is a product of the SMA collaboration between PTC, the SMA Foundation, and Roche.